Chloe E Atreya, MD
Medical Oncology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 3
- Since medical school
- 21 years
- Yale University School of Medicine, 2005
Offices
3 locations · University of California San Francisco · UCSF Medical Group Business Services · Regents of the University of California
Looking this up.
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Atreya’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A104445 · Current
Licensed to practise in California · since 2008 · expires 2027-12-31 · Yale University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Medical Oncology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$36,292
Medicare paid this office $36,292 for 115 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 85 | $27,590 | $126 |
| New patient visit (60+ min) | 23 | $3,705 | $161 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 22 | $1,228 | $28 |
| Return visit (30+ min) | 11 | $1,042 | $87 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 41 | $961 | $15 |
Who their Medicare patients are
115 Original Medicare patients in 2024. Average age 71 · Under 65 15% · 85 and older 10% · Women 61% · Also on Medicaid 25% · Health risk score 2.27. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: Cancer 75% · High blood pressure 64% · Depression 25% · Coronary heart disease 23% · Atrial fibrillation 17% · Chronic kidney disease 16% · Heart failure 12% · Stroke 11% · Diabetes 10% · COPD 10%.
The office billed $228,183, Medicare allowed $46,152 and paid $36,292; for 871 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 115 | 871 | 71 | 2.27 | $228,183 | $36,292 |
| 2023 | 80 | 256 | 71 | 2.59 | $159,134 | $25,603 |
| 2022 | 106 | 380 | 70 | 2.26 | $219,888 | $35,742 |
| 2021 | 80 | 783 | 69 | 2.29 | $201,345 | $30,693 |
| 2020 | 67 | 148 | 72 | 2.52 | $115,598 | $15,259 |
| 2019 | 67 | 132 | 72 | 2.39 | $110,265 | $14,023 |
| 2018 | 94 | 151 | 71 | 2.79 | $118,425 | $16,020 |
| 2017 | 86 | 160 | 70 | 2.54 | $114,093 | $16,021 |
| 2016 | 88 | 191 | 71 | 2.15 | $117,629 | $16,824 |
| 2015 | 64 | 179 | 67 | 2.18 | $107,501 | $15,458 |
| 2014 | 73 | 205 | 71 | 2.09 | $125,912 | $17,974 |
| 2013 | 43 | 115 | 70 | 1.73 | $61,457 | $9,621 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Long return visit (40+ min) | 62 | $20,170 | $128 |
| New patient visit (60+ min) | 17 | $2,595 | $153 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 15 | $1,391 | $28 |
2022: 3 services
| Long return visit (40+ min) | 72 | $25,167 | $128 |
| New patient visit (60+ min) | 30 | $4,561 | $152 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 43 | $3,528 | $28 |
2021: 3 services
| Long return visit (40+ min) | 58 | $16,854 | $130 |
| New patient visit (60+ min) | 31 | $5,156 | $166 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 29 | $1,710 | $29 |
2020: 3 services
| Long return visit (40+ min) | 44 | $9,087 | $98 |
| New patient visit (60+ min) | 23 | $3,500 | $152 |
| Return visit (30+ min) | 14 | $1,068 | $71 |
2019: 2 services
| Long return visit (40+ min) | 36 | $7,987 | $94 |
| New patient visit (60+ min) | 32 | $4,532 | $142 |
2018: 2 services
| Long return visit (40+ min) | 46 | $7,522 | $95 |
| New patient visit (60+ min) | 44 | $6,412 | $146 |
2017: 3 services
| Long return visit (40+ min) | 40 | $9,188 | $98 |
| New patient visit (60+ min) | 38 | $5,457 | $144 |
| Return visit (30+ min) | 11 | $555 | $46 |
2016: 3 services
| Return visit (30+ min) | 36 | $5,137 | $69 |
| New patient visit (60+ min) | 35 | $4,887 | $140 |
| Long return visit (40+ min) | 33 | $4,568 | $99 |
2015: 3 services
| Long return visit (40+ min) | 19 | $4,954 | $97 |
| Return visit (30+ min) | 30 | $4,668 | $69 |
| New patient visit (60+ min) | 23 | $3,358 | $146 |
2014: 4 services
| Long return visit (40+ min) | 29 | $8,548 | $98 |
| New patient visit (60+ min) | 30 | $4,442 | $148 |
| Return visit (30+ min) | 22 | $2,599 | $68 |
| Short return visit (20+ min) | 15 | $1,006 | $44 |
2013: 3 services
| Long return visit (40+ min) | 15 | $4,126 | $96 |
| New patient visit (60+ min) | 16 | $2,223 | $139 |
| Return visit (30+ min) | 14 | $1,498 | $60 |
Medicaid work
$11,322 in 2024
Medicaid paid $11,322 for 65 billed services this clinician did in 2024, up to 18 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 65 | $11,322 |
| 2024 | 65 | 1 | 18 | $11,322 |
| 2023 | 20 | 1 | 14 | $2,933 |
| 2021 | 16 | 1 | 12 | $2,293 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 20 | $2,933 |
2021
| Long return visit (40+ min) | 16 | $2,293 |
Drugs they prescribed that Part D paid
$820,404
Pharmacies billed $820,404 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
112 generic and 78 brand-name prescriptions · $820,404 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lonsurf | 43 | $398,744 | $9,273 |
| Sunitinib Malate | 25 | $113,160 | $4,526 |
| Eliquis | 13 | $13,182 | $1,014 |
| Ondansetron | 20 | $313 | $16 |
| Prochlorperazine Maleate | 24 | $163 | $7 |
Year by year
| 2024 | 190 | 31 | None | 41% | $820,404 |
| 2023 | 162 | 25 | 0% (0) | 28% | $728,762 |
| 2022 | 142 | 30 | None | 18% | $471,290 |
| 2021 | 141 | 30 | None | 16% | $234,889 |
| 2020 | 182 | 27 | None | 30% | $274,795 |
| 2019 | 142 | 35 | None | 25% | $180,094 |
| 2018 | 133 | 30 | None | 32% | $285,669 |
| 2017 | 164 | 33 | None | None | $181,060 |
| 2016 | 105 | 26 | None | 13% | $105,259 |
| 2015 | 123 | 26 | None | None | $58,166 |
| 2014 | 114 | 21 | None | 14% | $64,583 |
| 2013 | 32 | None | None | None | $1,597 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Sunitinib Malate | 23 | $236,679 | $10,290 |
| Lonsurf | 20 | $231,372 | $11,569 |
| Imatinib Mesylate | 32 | $8,170 | $255 |
| Doxycycline Hyclate | 11 | $702 | $64 |
| Ondansetron | 11 | $214 | $19 |
| Prochlorperazine Maleate | 14 | $184 | $13 |
2022: 4 drugs
| Lonsurf | 13 | $192,380 | $14,798 |
| Imatinib Mesylate | 35 | $54,408 | $1,555 |
| Ondansetron | 20 | $442 | $22 |
| Prochlorperazine Maleate | 22 | $223 | $10 |
2021: 3 drugs
| Imatinib Mesylate | 43 | $62,925 | $1,463 |
| Synthroid | 11 | $564 | $51 |
| Prochlorperazine Maleate | 16 | $154 | $10 |
2020: 6 drugs
| Lonsurf | 12 | $155,370 | $12,948 |
| Imatinib Mesylate | 35 | $34,674 | $991 |
| Xarelto | 14 | $6,422 | $459 |
| Synthroid | 14 | $738 | $53 |
| Ondansetron | 21 | $375 | $18 |
| Duloxetine | 12 | $136 | $11 |
2019: 5 drugs
| Lonsurf | 12 | $110,482 | $9,207 |
| Imatinib Mesylate | 24 | $50,431 | $2,101 |
| Ondansetron | 19 | $509 | $27 |
| Prochlorperazine Maleate | 14 | $268 | $19 |
| Olanzapine | 11 | $99 | $9 |
2018: 3 drugs
| Lonsurf | 18 | $149,285 | $8,294 |
| Ondansetron | 16 | $193 | $12 |
| Prochlorperazine Maleate | 16 | $86 | $5 |
2017: 3 drugs
| Ondansetron | 27 | $501 | $19 |
| Lidocaine-Prilocaine | 16 | $455 | $28 |
| Prochlorperazine Maleate | 27 | $184 | $7 |
2016: 4 drugs
| Lidocaine-Prilocaine | 11 | $321 | $29 |
| Ondansetron | 21 | $266 | $13 |
| Loperamide | 12 | $107 | $9 |
| Prochlorperazine Maleate | 15 | $87 | $6 |
2015: 2 drugs
| Ondansetron | 18 | $312 | $17 |
| Prochlorperazine Maleate | 19 | $115 | $6 |
2014: 4 drugs
| Ondansetron | 22 | $588 | $27 |
| Lidocaine-Prilocaine | 13 | $331 | $25 |
| Prochlorperazine Maleate | 26 | $179 | $7 |
| Lorazepam | 17 | $87 | $5 |
Money from drug and device companies
$2,899 in 2024
| 2024 | 3 | 3 | $2,625 | $2,899 |
| 2023 | 1 | 1 | $2,625 | $2,625 |
| 2021 | 1 | 1 | $1,890 | $1,890 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| F. Hoffmann-La Roche AG | None | $2,625 | 1 payment
|
| Array Biopharma | None | $139 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $135 | 1 payment
|
See all 3 published payments
| F. Hoffmann-La Roche AG | Consulting · 2024-11-05 | None | $2,625 |
| AstraZeneca Pharmaceuticals LP | Meals · 2024-01-19 | None | $135 |
| Array Biopharma | Meals · 2024-01-19 | None | $139 |
See earlier years (2023, 2021)
2023: $2,625
| F. Hoffmann-La Roche AG | None | $2,625 | 1 payment
|
2021: $1,890
| Array Biopharma | Braftovi | $1,890 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Merck Sharp & Dohme Corporation · Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Metastatic Colorectal Cancer · 2019 | Their institution | $1,354,000 |
| Merck Sharp & Dohme Corporation · Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Metastatic Colorectal Cancer · 2021 | Their institution | $1,266,805 |
| Merck Sharp & Dohme Corporation · Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Metastatic Colorectal Cancer · 2020 | Their institution | $439,771 |
| Merck Sharp & Dohme LLC · Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Metastatic Colorectal Cancer · 2022 | Their institution | $414,856 |
| Merck Sharp & Dohme Corporation · A Phase II Study of Preoperative Immunotherapy in Patients With Colorectal Cancer and Resectable Hepatic Metastases · 2019 | Their institution | $271,397 |
| PFIZER INC. · Phase III Trial of Encorafenib Binimetinib and Nivolumab in Microsatellite Stable Brafv600e Metastatic Colorectal Cancer · 2021 | Their institution | $263,097 |
| Merck Sharp & Dohme LLC · Study Name#Otsp A Phase 2 Study of Perioperative Immunotherapy in Patients With Colorectal Cancer and Resectable Hepatic Metastases · 2024 | Their institution | $226,792 |
| E.R. Squibb & Sons, L.L.C. · Phase I Iia 2l 3l Crc Mss Kras Nivo Mek Combo Trametinib Novartis · 2019 | Their institution | $219,134 |
| Merck Sharp & Dohme LLC · A Phase II Study of Preoperative Immunotherapy in Patients With Colorectal Cancer and Resectable Hepatic Metastases · 2022 | Their institution | $179,316 |
| Merck Sharp & Dohme LLC · A Phase II Study of Preoperative Immunotherapy in Patients With Colorectal Cancer and Resectable Hepatic Metastases · 2024 | Their institution | $178,796 |
| Merck Sharp & Dohme LLC · A Phase II Study of Preoperative Immunotherapy in Patients With Colorectal Cancer and Resectable Hepatic Metastases · 2023 | Their institution | $106,835 |
| Merck Sharp & Dohme LLC · Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer · 2025 | Their institution | $99,302 |
| Merck Sharp & Dohme LLC · Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Metastatic Colorectal Cancer · 2023 | Their institution | $99,302 |
| E.R. Squibb & Sons, L.L.C. · Phase I Iia 2l 3l Crc Mss Kras Nivo Mek Combo Trametinib Novartis · 2022 | Their institution | $85,689 |
| PFIZER INC. · Phase III Trial of Encorafenib Binimetinib and Nivolumab in Microsatellite Stable Brafv600e Metastatic Colorectal Cancer · 2022 | Their institution | $78,728 |
| E.R. Squibb & Sons, L.L.C. · Phase I/II Trial of Encorafenib, Binimetinib and Nivolumab in Microsatellite Stable Brafv600e Metastatic Colorectal Cancer · 2023 | Their institution | $69,231 |
| E.R. Squibb & Sons, L.L.C. · Phase I Iia 2l 3l Crc Mss Kras Nivo Mek Combo Trametinib Novartis · 2020 | Their institution | $68,569 |
| Amgen Inc. · Optimizing Panitumumab- Containing Combination Therapies for Braf V600e Mutated Metastatic Colorectal · 2024 | Their institution | $55,200 |
| Merck Sharp & Dohme Corporation · A Phase II Study of Pembrolizumab Mk-3475 As Monotherapy in Subjects With Previously Treated Locally Advanced Unresectable Or Metastatic Stage IV Mismatched Repair Deficient Or Microsatellite Instability-High Colorectal Carcinoma Keynote-164 · 2020 | Their institution | $53,428 |
| Merck Sharp & Dohme LLC · (Otsp) A Phase 2 Study of Perioperative Immunotherapy in Patients With Colorectal Cancer and Resectable Hepatic Metastases · 2025 | Their institution | $42,346 |
| Novartis Pharmaceuticals Corporation · An Open Label Four Part Phase I and Or II Study To Investigate the Safety Pharmacokinetics Pharmacodynamics and Clinical Activity of the Mek Inhibitor Gsk1120212 Braf Inhibitor Gsk2118436 and the Anti Egfr Antibody Panitumumab in Combination in Subjects With Braf Mutation V600e Positive Colorectal Cancer and in Subjects With Crc With Secondary Resistance To Prior Anti Egfr Therapy · 2021 | Their institution | $36,843 |
| E.R. Squibb & Sons, L.L.C. · Phase I Iia 2l 3l Crc Mss Kras Nivo Mek Combo Trametinib Novartis · 2021 | Their institution | $36,588 |
| Merck Sharp & Dohme Corporation · A Phase II Study of Pembrolizumab Mk-3475 As Monotherapy in Subjects With Previously Treated Locally Advanced Unresectable Or Metastatic Stage IV Mismatched Repair Deficient Or Microsatellite Instability-High Colorectal Carcinoma Keynote-164 · 2021 | Their institution | $28,732 |
| Merck Sharp & Dohme Corporation · A Phase 1,2, First-in-Human, Open-Label, Dose Escalation Study of Gb1275 Monotherapy and in Combination With An Anti-Pd-1 Antibody in Patients With Specified Advanced Solid Tumors Or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma, Followed By Basket Expansion of Gb1275 With Standard of Care Or in Combination With An Anti-Pd-1 Antibody in Patients With Specified Metastatic Solid Tumors. · 2021 | Their institution | $16,200 |
| E.R. Squibb & Sons, L.L.C. · A Study of Nivolumab in Combination With Trametinib With Or Without Ipilimumab in Participants With Previously Treated Metastatic Colorectal Cancers · 2025 | Their institution | $14,487 |
| E.R. Squibb & Sons, L.L.C. · Phase I/Iia 2l/3l Crc Mss Kras Nivo/Mek Combo (Trametinib/Novartis) · 2024 | Their institution | $12,823 |
| Merck Sharp & Dohme Corporation · A Phase II Study of Pembrolizumab Mk-3475 As Monotherapy in Subjects With Previously Treated Locally Advanced Unresectable Or Metastatic Stage IV Mismatched Repair Deficient Or Microsatellite Instability-High Colorectal Carcinoma Keynote-164 · 2019 | Their institution | $6,612 |
| Novartis Pharmaceuticals Corporation · An Open Label Four Part Phase I and Or II Study To Investigate the Safety Pharmacokinetics Pharmacodynamics and Clinical Activity of the Mek Inhibitor Gsk1120212 Braf Inhibitor Gsk2118436 and the Anti Egfr Antibody Panitumumab in Combination in Subjects W · 2019 | Their institution | $6,054 |
| E.R. Squibb & Sons, L.L.C. · Phase I/Iia 2l/3l Crc Mss Kras Nivo/Mek Combo (Trametinib/Novartis) · 2023 | Their institution | $635 |
| E.R. Squibb & Sons, L.L.C. · Phase I/Iia 2l/3l Crc Mss Kras Nivo/Mek Combo (Trametinib/Novartis) · 2022 | Their institution | $317 |
| Merck Sharp & Dohme LLC · A Phase II Study of Pembrolizumab Mk-3475 As Monotherapy in Subjects With Previously Treated Locally Advanced Unresectable Or Metastatic Stage IV Mismatched Repair Deficient Or Microsatellite Instability-High Colorectal Carcinoma Keynote-164 · 2022 | Their institution | $221 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 74.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1326058777
- Licence
- CA A104445California A104445: Current · expires 2027-12-31
- Trained
- Yale University School of Medicine, 2005 · 21 years ago
- Group
- University of California San Francisco · UCSF Medical Group Business Services · Regents of the University of California
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X)
- Mailing address
- 1600 Divisadero St, 4th Floor, Box 1705, San Francisco, CA, 94115
- NPI first listed
- 2006-08-08
- NPI last updated
- 2012-11-30
This is when the NPI record was last certified, not a medical board exam.